Logo image of ECT.AS

EUROCASTLE INVESTMENT LTD (ECT.AS) Stock Price, Forecast & Analysis

Europe - Euronext Amsterdam - AMS:ECT - GB00B94QM994

12.2 EUR
-0.9 (-6.87%)
Last: 12/8/2025, 7:00:00 PM
Fundamental Rating

4

ECT gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 77 industry peers in the Real Estate Management & Development industry. ECT is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. ECT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

ECT had positive earnings in the past year.
ECT had a negative operating cash flow in the past year.
In multiple years ECT reported negative net income over the last 5 years.
In the past 5 years ECT always reported negative operating cash flow.
ECT.AS Yearly Net Income VS EBIT VS OCF VS FCFECT.AS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

1.2 Ratios

The Return On Assets of ECT (1.54%) is comparable to the rest of the industry.
The Return On Equity of ECT (1.57%) is comparable to the rest of the industry.
ECT has a Return On Invested Capital of 1.17%. This is comparable to the rest of the industry: ECT outperforms 44.16% of its industry peers.
Industry RankSector Rank
ROA 1.54%
ROE 1.57%
ROIC 1.17%
ROA(3y)-1.72%
ROA(5y)-1.28%
ROE(3y)-1.77%
ROE(5y)-1.34%
ROIC(3y)N/A
ROIC(5y)N/A
ECT.AS Yearly ROA, ROE, ROICECT.AS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40

1.3 Margins

Looking at the Profit Margin, with a value of 28.98%, ECT is in the better half of the industry, outperforming 70.13% of the companies in the same industry.
ECT's Profit Margin has been stable in the last couple of years.
ECT has a Operating Margin (28.98%) which is comparable to the rest of the industry.
In the last couple of years the Operating Margin of ECT has remained more or less at the same level.
ECT's Gross Margin of 91.37% is amongst the best of the industry. ECT outperforms 85.71% of its industry peers.
In the last couple of years the Gross Margin of ECT has grown nicely.
Industry RankSector Rank
OM 28.98%
PM (TTM) 28.98%
GM 91.37%
OM growth 3Y-7.21%
OM growth 5Y-1.26%
PM growth 3Y-7.21%
PM growth 5Y-1.2%
GM growth 3Y-0.87%
GM growth 5Y19.91%
ECT.AS Yearly Profit, Operating, Gross MarginsECT.AS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for ECT has been increased compared to 1 year ago.
ECT has less shares outstanding than it did 5 years ago.
There is no outstanding debt for ECT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ECT.AS Yearly Shares OutstandingECT.AS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
ECT.AS Yearly Total Debt VS Total AssetsECT.AS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

Based on the Altman-Z score of -82.02, we must say that ECT is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -82.02, ECT is doing worse than 92.21% of the companies in the same industry.
There is no outstanding debt for ECT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -82.02
ROIC/WACCN/A
WACCN/A
ECT.AS Yearly LT Debt VS Equity VS FCFECT.AS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M 500M

2.3 Liquidity

ECT has a Current Ratio of 27.47. This indicates that ECT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 27.47, ECT belongs to the top of the industry, outperforming 98.70% of the companies in the same industry.
A Quick Ratio of 27.47 indicates that ECT has no problem at all paying its short term obligations.
ECT has a Quick ratio of 27.47. This is amongst the best in the industry. ECT outperforms 98.70% of its industry peers.
Industry RankSector Rank
Current Ratio 27.47
Quick Ratio 27.47
ECT.AS Yearly Current Assets VS Current LiabilitesECT.AS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

2

3. Growth

3.1 Past

ECT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 154.32%, which is quite impressive.
Measured over the past years, ECT shows a decrease in Earnings Per Share. The EPS has been decreasing by -2.08% on average per year.
Looking at the last year, ECT shows a very strong growth in Revenue. The Revenue has grown by 153.50%.
The Revenue for ECT have been decreasing by -52.85% on average. This is quite bad
EPS 1Y (TTM)154.32%
EPS 3Y-15.5%
EPS 5Y-2.08%
EPS Q2Q%322.22%
Revenue 1Y (TTM)153.5%
Revenue growth 3Y-25.89%
Revenue growth 5Y-52.85%
Sales Q2Q%185.29%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ECT.AS Yearly Revenue VS EstimatesECT.AS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M
ECT.AS Yearly EPS VS EstimatesECT.AS Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 0 1 2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 34.86, the valuation of ECT can be described as expensive.
ECT's Price/Earnings is on the same level as the industry average.
The average S&P500 Price/Earnings ratio is at 26.34. ECT is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE 34.86
Fwd PE N/A
ECT.AS Price Earnings VS Forward Price EarningsECT.AS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ECT.AS Per share dataECT.AS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 15 20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ECT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EUROCASTLE INVESTMENT LTD

AMS:ECT (12/8/2025, 7:00:00 PM)

12.2

-0.9 (-6.87%)

Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryReal Estate Management & Development
Earnings (Last)08-05 2025-08-05
Earnings (Next)04-22 2026-04-22
Inst Owners5.78%
Inst Owner ChangeN/A
Ins Owners6.8%
Ins Owner ChangeN/A
Market Cap12.20M
Revenue(TTM)1.19M
Net Income(TTM)346.00K
Analysts84
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 34.86
Fwd PE N/A
P/S 10.22
P/FCF N/A
P/OCF N/A
P/B 0.55
P/tB 0.55
EV/EBITDA N/A
EPS(TTM)0.35
EY2.87%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-5.78
FCFYN/A
OCF(TTM)-5.78
OCFYN/A
SpS1.19
BVpS22.09
TBVpS22.09
PEG (NY)N/A
PEG (5Y)N/A
Graham Number13.19
Profitability
Industry RankSector Rank
ROA 1.54%
ROE 1.57%
ROCE 1.57%
ROIC 1.17%
ROICexc 2.68%
ROICexgc 4.82%
OM 28.98%
PM (TTM) 28.98%
GM 91.37%
FCFM N/A
ROA(3y)-1.72%
ROA(5y)-1.28%
ROE(3y)-1.77%
ROE(5y)-1.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-7.21%
OM growth 5Y-1.26%
PM growth 3Y-7.21%
PM growth 5Y-1.2%
GM growth 3Y-0.87%
GM growth 5Y19.91%
F-Score5
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 27.47
Quick Ratio 27.47
Altman-Z -82.02
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)154.32%
EPS 3Y-15.5%
EPS 5Y-2.08%
EPS Q2Q%322.22%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)153.5%
Revenue growth 3Y-25.89%
Revenue growth 5Y-52.85%
Sales Q2Q%185.29%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y154.49%
EBIT growth 3Y-31.23%
EBIT growth 5Y-53.45%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-52.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-52.2%
OCF growth 3YN/A
OCF growth 5YN/A

EUROCASTLE INVESTMENT LTD / ECT.AS FAQ

Can you describe the business of EUROCASTLE INVESTMENT LTD?

Eurocastle Investment Ltd is a GG-based company operating in Real Estate Management & Development industry. Eurocastle Investment Limited is a closed-ended investment company. The firm is focused on opportunistic real estate in Greece with a plan to expand across Southern Europe. The firm is in the early stages of pursuing its investment activities. The firm's investment manager is FIG LLC.


Can you provide the latest stock price for EUROCASTLE INVESTMENT LTD?

The current stock price of ECT.AS is 12.2 EUR. The price decreased by -6.87% in the last trading session.


What is the ChartMill rating of EUROCASTLE INVESTMENT LTD stock?

ECT.AS has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 4 out of 10.